Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

NCT01922661 ↗

Phase 1 Completed 24 enrolled Regeneron Pharmaceuticals

RandomizedSingle-groupTriple-blindTreatment

Summary

The primary objective of the study is to assess the safety and tolerability of single ascending doses of subcutaneously (SC) administered REGN1908-1909 in allergic, adult subjects.

Timeline

Start: 2013-08
Primary completion: 2014-05
Completion: 2014-05

Publications

Kamal MA, Dingman R, Wang CQ, Lai CH, Rajadhyaksha M, DeVeaux M, Orengo JM, Radin A, Davis JD. REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics. Clin Transl Sci. 2021 Nov;14(6):2440-2449. doi: 10.1111/cts.13112. Epub 2021 Aug 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	REGN1908-1909	Monoclonal antibody	150 mg	Subcutaneous
Subject	REGN1908-1909	Monoclonal antibody	300 mg	Subcutaneous
Subject	REGN1908-1909	Monoclonal antibody	600 mg	Subcutaneous

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

Summary

Timeline

Publications

Drugs

Indications